OpenAI It presented an AI model specifically designed for scientific research and drug discovery.
The new GPT-Rosalind device features improved tool usability and a deeper understanding of chemistry, protein engineering and genomics, the company said on Thursday (April 16). press release.
With this new AI model, OpenAI aims to help scientists overcome current limitations of complex research workflows and reduce the time it takes to move a new drug from targeted discovery to regulatory approval, which currently ranges from 10 to 15 years, according to the release.
“We believe advanced AI systems can help researchers move through workflows faster — not just by making existing work more efficient, but by helping scientists explore more possibilities, superficial connections that might otherwise be missed, and arrive at better hypotheses sooner,” the company said in the statement.
OpenAI offers GPT-Rosalind as a research preview in ChatGPT, Codex Alimentarius and Application Programming Interface (API) for eligible customers through the company’s Trusted Access Program. It has also introduced a freely accessible Codex Life Sciences Research Plugin that helps scientists connect models to more than 50 scientific instruments and data sources.
The company works with clients such as Amgen, accidentthe Allen Institute, Thermo Fisher Scientific and others to apply GPT-Rosalind in research and discovery, according to the release.
Advertisement: Scroll to continue
Old brewery“Our unique collaboration with OpenAI enables us to apply their most advanced capabilities and tools in new and innovative ways with the potential to accelerate how we deliver medicines to patients,” Amgen’s senior vice president of AI and Data said in the release.
the PYMNTS INTELLIGENCE a report “Generative AI can advance health and revolutionize healthcare“I find that generative AI innovations expand researchers’ capabilities, accelerating drug discovery and diagnosis.
It was reported in February that Pharmaceutical companies It is reshaping its operating models around AI to accelerate clinical trials and regulatory submissions. Additionally, AI is reshaping drug discovery, clinical strategy, and manufacturing optimization.
In March, Pharmaceutical Titan Eli Lilly It said it had concluded a deal worth $2.75 billion with… Insilico Medicine To use artificial intelligence to accelerate “the discovery and development of new treatments.”
